Vaccines against MERS-COV

 

Investigated molecular dynamics simulations of targeting, evaluating their interaction with corresponding major histocompatibility complex class I molecules. They potentially elicit immune responses (176). Recombinant vaccine can be designed using rabies virus (RV) as viral vector. RV can be engineered to express the MERS-CoV S1 protein on its surface so as to induce an immune response against MERS-CoV. RV vector-based vaccines against MERS-COV can elicit a faster antibody response as well as higher degrees of cell-mediated immunity than Gram-positive enhancer matrix (GEM) particle-based vaccine. However, the latter can elicit a very high antibody response at lower doses (167). Therefore, the degree of humoral and cellular immune responses produced by such vaccines depends on the vehicle used.

Dual vaccines have become more popular recently. Among them, the rabies virus-based vaccine platform is being used to develop vaccines against emerging infectious diseases. The dual vaccine developed from inactivated rabies virus particles expressing the MERS-CoV S1 domain of the S protein was found to induce immune responses to both MERS-CoV and rabies virus. Vaccinated mice were found to be fully protected against MERS-CoV challenge (169).